Baicheng Pharmaceuticals: Subsidiary Saimo Pharmaceuticals plans to win bids for 12 varieties in the 11th round of national drug centralized procurement.

On November 3rd, Baicheng Pharmaceutical stated during a visit from five institutions including Hongdao Investment and Yongquan Investment, that its subsidiary Saimo Pharmaceutical has a construction area of approximately 260 acres. It has completed pharmaceutical GMP standard factory buildings and supporting laboratories covering an area of 163,000 square meters. The company has completed validation for 617 projects and applied for registration for 461 projects, ranking among the top in the country. In the eleventh batch of national centralized drug procurement, Saimo Pharmaceutical has 12 varieties that are expected to win bids, with 4 products as the marketing authorization holder and 8 as contract manufacturing organizations. This planned bid-winning demonstrates Saimo Pharmaceutical's production capacity and market competitiveness, and in the future, it will accelerate the release of Saimo Pharmaceutical's production capacity and further increase market share.